c144-ls
mAbexperimentalCOVID-19
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 11, 2021 (NCT04700163)
Timeline
Indications
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05393999 | Phase 2 | Nov 29, 2021 | Imperial College London, University of London, University of Oxford |
| NCT04700163 | Phase 1 | Jan 11, 2021 | Rockefeller University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Rockefeller University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1